Oxymetholone (Anadrol): Potent Oral Anabolic Research

Research Disclaimer: Oxymetholone is sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

Oxymetholone (17α-methyl-2-hydroxymethylene-17β-hydroxy-5α-androstan-3-one; Anadrol-50) is one of the most potent oral anabolic steroids in research, with an A:A ratio of ~320:1 in the Hershberger assay and documented lean mass effects at doses as low as 50 mg/day in clinical anemias. Its pharmacology is unusual: it is not aromatized to estradiol but nonetheless produces estrogen-like effects (water retention, gynecomastia risk) — now attributed to direct estrogen receptor partial agonist activity of oxymetholone itself and/or its metabolites. FDA-approved for aplastic anemia and HIV wasting, oxymetholone also has the highest hepatotoxicity risk in the oral anabolic class.

Table of Contents#

1. Structure: 2-Hydroxymethylene Modification
2. The Paradox: Estrogenic Without Aromatization
3. Erythropoietic Effects: Mechanism and Evidence
4. Anabolic Potency: The Most Anabolic Oral
5. Hepatotoxicity Profile
6. Clinical Research: Aplastic Anemia and HIV Wasting
7. Research Protocols
8. Key References

Structure: 2-Hydroxymethylene Modification#

Oxymetholone's unique structural features:

Base scaffold: 17α-methyl-5α-androstane (same family as stanozolol, but different ring modifications)

2-Hydroxymethylene group:

• At C2 position: -CH=CH-OH (enol) group; tautomers between hydroxymethylene (enol) and formyl-methyl (keto) forms
• This group is the primary structural determinant of oxymetholone's unique pharmacology
• 5α-reduced A ring → no Δ4-3-ketone → NOT aromatizable (aromatase cannot act on saturated A ring)
• Yet produces estrogenic effects → the paradox (see section below)

C17α-methyl:

• Standard oral bioavailability mechanism (blocks 17β-HSD oxidation)
• Primary source of hepatotoxicity: BSEP inhibition + CYP reactive metabolite generation

Pyrazoline analogue note: Unlike stanozolol (which uses a nitrogen-containing pyrazole ring fusion), oxymetholone retains a single A-ring with the 2-hydroxymethylene substituent. Different structural strategy, similar goal of metabolic resistance.

The Paradox: Estrogenic Without Aromatization#

The observation: Oxymetholone users frequently report water retention, gynecomastia, and estrogenic effects — at levels that exceed what would be expected from a non-aromatizing androgen. AIs (anastrozole, letrozole) do not fully prevent these effects, confirming they are not E2-mediated.

Current mechanistic explanation:

1. Direct ER partial agonism by oxymetholone:

   • Oxymetholone binds ERα directly (partial agonist, not metabolite)
   • The 2-hydroxymethylene group creates a phenol-like partial structure that may weakly mimic phenolic ring A of estradiol at the ER binding pocket
   • Cell assays: oxymetholone activates ERE (estrogen response element)-luciferase at ~10⁻⁶ M (much weaker than E2, but at pharmacological tissue concentrations could be relevant)

2. Metabolite ER activity:

   • Oxymetholone → hepatic metabolism → possible estrogenically active metabolites
   • 2α-hydroxymethyl metabolite may contribute

3. High E2 at baseline (if testosterone not suppressed):

   • Oxymetholone strongly suppresses HPTA → reduces testosterone → reduces aromatase substrate → actually DECREASES E2 at high doses despite subjective estrogenic feel

Research implication: Oxymetholone is a pharmacological tool for studying non-aromatization-based estrogenicity — direct ER agonism by an androgen, independent of CYP19A1.

Erythropoietic Effects: Mechanism and Evidence#

Oxymetholone is the most potent erythropoiesis-stimulating androgen studied:

Mechanisms (multiple converging):

1. Direct EPO gene stimulation:

   • AR activation in renal peritubular cells → upregulates EPO gene transcription
   • Oxymetholone produces greater EPO stimulation than other androgens at comparable anabolic doses
   • Serum EPO: increases ~2–3× above baseline within 2–4 weeks of oxymetholone treatment

2. Direct bone marrow progenitor effect:

   • Androgens → direct AR activation in BFU-E (burst-forming unit-erythroid) and CFU-E (colony-forming unit-erythroid) progenitors
   • Promotes erythroid progenitor proliferation and differentiation independent of EPO
   • Oxymetholone shows particularly strong direct marrow effects (mechanism not fully characterized)

3. Increased iron utilization:

   • Androgens → stimulate iron absorption (intestinal) and transfer to erythropoietic marrow
   • Hepcidin (iron regulatory hormone) may be downregulated

Clinical evidence:

• Aplastic anemia: oxymetholone 50–200 mg/day → hemoglobin +2–4 g/dL in responders (~50–60% response rate)
• Myelofibrosis, Diamond-Blackfan anemia: partial response in some cases
• HIV wasting trials: hemoglobin increase + lean mass increase (dual benefit)

Anabolic Potency: The Most Anabolic Oral#

Hershberger assay data:

• Oxymetholone A:A ratio: ~320:1 in some published assays
• This makes it the most anabolic oral androgen studied

Comparison table:

Caveat: The A:A ratio measures muscle vs. prostate selectivity, not absolute potency. Oxymetholone's ~320:1 means at equivalent prostate stimulation, it produces ~320× more anabolic effect than testosterone — but at 50–150 mg/day doses, significant androgenic and hepatotoxic effects still occur due to the high absolute dose.

Lean mass evidence:

• HIV wasting: oxymetholone 50, 100, 150 mg/day × 30 weeks → +4.2, +7.3, +8.3 kg lean mass respectively
• Aplastic anemia: body weight gain + muscle mass gain parallels anemia response
• Most potent lean mass effect per unit time of any oral androgen studied

Hepatotoxicity Profile#

Oxymetholone has the highest hepatotoxicity risk among commonly studied oral anabolics:

Mechanisms (same as all C17α-alkylated compounds, but more severe):

• BSEP inhibition → intrahepatic bile accumulation → cholestatic injury
• CYP3A4 → reactive metabolites → GSH depletion → mitochondrial damage

Specific to oxymetholone — higher severity:

• High doses (50–150 mg/day) → higher hepatic concentration than other orals at therapeutic doses
• Peliosis hepatis: most frequently reported in oxymetholone case series
• Hepatocellular carcinoma (HCC): oxymetholone historically the most associated oral androgen with HCC (case reports and case series, not RCT)
• Liver histology: canalicular cholestasis, peliosis, nodular regenerative hyperplasia in long-term use

Clinical enzyme data:

• ALT/AST elevation: nearly universal at doses >50 mg/day beyond 4–6 weeks
• Typically reversible on cessation (within 4–12 weeks)
• Severe cases: jaundice, cholestatic hepatitis, rarely acute liver failure

TUDCA note: Some hepatoprotective benefit with TUDCA co-treatment, but not sufficient to fully prevent oxymetholone hepatotoxicity at standard doses.

Clinical Research: Aplastic Anemia and HIV Wasting#

FDA-approved indications (Anadrol-50):

1. Aplastic anemia
2. Anemia due to bone marrow failure (myelofibrosis, Diamond-Blackfan)
3. HIV/AIDS wasting (off-label but well-studied)

HIV wasting research (Hengge et al., 2003):

• 89 HIV-positive patients, oxymetholone 50, 100, or 150 mg/day × 30 weeks
• Lean mass: dose-dependent increase (+4.2, +7.3, +8.3 kg)
• Fat mass: no significant change
• CD4 count: no significant effect (important — does not worsen HIV progression)
• Hepatotoxicity: dose-dependent ALT elevation; reversed on dose reduction

Research Protocols#

Erythropoiesis mechanism study (rats)#

Direct ER agonism: oxymetholone in ERE-reporter cells#

Key References#

1. Hengge UR, et al. (2003). "Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus." Journal of Steroid Biochemistry and Molecular Biology, 86(5):459–465.

2. Shahidi NT. (2001). "A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids." Clinical Therapeutics, 23(9):1355–1390.

3. Tan RS & Vasudevan D. (2003). "Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse." Fertility and Sterility, 79(1):203–205.

Research Use Only: Oxymetholone is sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science